The approval was based on data from the SELECT-AXIS 2 trial that included adults with active nr-axSpA who had an inadequate response or intolerance to TNF blocker therapy. The Food and Drug ...

Axial spondyloarthritis is a chronic inflammatory disease that affects the spine, causing back pain, limited mobility, and structural damage. 6 It consists of two subsets that have been clinically ...

- AbbVie has also submitted results from two studies of upadacitinib in adult patients with ankylosing spondylitis (AS) to request label enhancements in the European Union (EU) - RINVOQ is approved ...

(RTTNews) - AbbVie (ABBV) said Friday that it has submitted applications seeking approvals for upadacitinib (RINVOQ, 15 mg once daily) to the U.S. Food and Drug Administration and the European ...

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Full 1-year ...

BRUSSELS and ATLANTA, Jan. 18, 2022 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced positive top-line interim analysis results showing that the Phase 3 BE MOBILE 1 study met ...

Credit: Getty Images. The COAST-X trial was conducted in 305 biologic disease-modifying antirheumatic drug (bDMARD)-naïve patients with nr-axSpA. Eli Lilly has announced top-line results from a phase ...

Ankylosing Spondylitis (AS) is the leading chronic progressive inflammatory rheumatic disease that involves the sacroiliac joints (SIJs) and the spinal column but is often difficult to recognize in ...

AbbVie (NYSE: ABBV) today announced that the European Commission (EC) has approved RINVOQ ® (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of active non-radiographic axial ...